STOCK TITAN
  1. Home
  2. Sec-filings
  3. OSRH
  4. [8-K] OSR Health, Inc. Reports Material Event

OSR Health (Nasdaq: OSRH) appeals delisting as trading halt nears

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

OSR Health, Inc. (OSRH) reports an update on its Nasdaq listing status. Nasdaq staff previously determined to delist the company’s common stock and warrants from the Nasdaq Capital Market for non-compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). On August 25, 2026, OSR Health requested a hearing before a Nasdaq Hearings Panel to appeal the delisting determination and asked for continued listing of its securities. The company states that trading in its securities is still scheduled to be suspended at the opening of business on August 26, 2026, despite the hearing request. The hearing request is expected to stay the filing of a Form 25-NSE, delaying formal delisting and deregistration while the Panel reviews the case. OSR Health plans to present a compliance plan but cautions there is no assurance the Panel will grant continued listing or that it will regain compliance.

Positive

  • None.

Negative

  • Nasdaq delisting risk: Nasdaq staff has determined to delist OSR Health’s securities for non-compliance with the minimum bid price requirement, and trading is scheduled to be suspended on August 26, 2026, with no assurance the company will regain compliance or maintain its Nasdaq listing.

Insights

Analyzing...

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Par value per share $0.0001 per share Par value of OSR Health common stock
Warrant exercise price $11.50 per share Exercise price of OSR Health redeemable warrants
Trading suspension date August 26, 2026 Scheduled date for suspension of trading in OSR Health securities on Nasdaq
Nasdaq Listing Rule 5550(a)(2) regulatory
"non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2)"
minimum bid price requirement regulatory
"for non-compliance with the minimum bid price requirement set forth in"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Hearings Panel regulatory
"request for a hearing before a Nasdaq Hearings Panel (the “Panel”)"
A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.
Form 25-NSE regulatory
"expected to stay the filing of a Form 25-NSE, and therefore the formal delisting"
Form 25‑NSE is an official filing used to notify the stock exchange that a company’s securities are being removed from trading on that exchange, similar to handing in a key when a shop closes. Investors care because removal ends public trading on that venue, often cutting liquidity and making it harder to buy or sell shares, which can affect a stock’s price and how quickly investors can access cash or exit positions.
Emerging growth company regulatory
"or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

Why is OSR Health, Inc. (OSRH) facing delisting from Nasdaq?
OSR Health is facing delisting because Nasdaq staff determined the company is not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for its common stock and warrants listed on the Nasdaq Capital Market.

What action did OSR Health (OSRH) take on August 25, 2026 regarding Nasdaq delisting?
On August 25, 2026, OSR Health submitted a request for a hearing before a Nasdaq Hearings Panel, appealing Nasdaq staff’s delisting determination and requesting the continued listing of the company’s common stock and warrants on Nasdaq.

When will trading in OSR Health (OSRH) securities be suspended on Nasdaq?
OSR Health states that, despite the hearing request, suspension of trading in its securities on Nasdaq remains scheduled for the opening of business on August 26, 2026, because the company had already been granted a second 180-day compliance period.

What is the effect of OSR Health’s hearing request on Form 25-NSE and formal delisting?
The company expects that the timely hearing request will stay the filing of a Form 25-NSE, which would formally delist and deregister its securities from Nasdaq, pending the Nasdaq Hearings Panel’s decision on OSR Health’s appeal.

Can OSR Health (OSRH) guarantee it will remain listed on Nasdaq?
No. OSR Health explicitly states there can be no assurance that the Nasdaq Hearings Panel will grant its request for continued listing or that the company will regain or maintain compliance with Nasdaq’s listing requirements.

What securities of OSR Health are currently listed and affected by the Nasdaq action?
The affected securities are OSR Health’s common stock, par value $0.0001 per share (trading symbol OSRH) and its redeemable warrants, exercisable for common stock at $11.50 per share (trading symbol OSRHW), both listed on The Nasdaq Stock Market LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0001840425 0001840425 2026-08-25 2026-08-25 0001840425 OSRH:CommonStockParValue0.0001PerShareMember 2026-08-25 2026-08-25 0001840425 OSRH:RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember 2026-08-25 2026-08-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 25, 2026

 

OSR HEALTH, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-41390   84-5052822
(State or Other Jurisdiction   (Commission File Number)   (IRS Employer
of Incorporation)       Identification No.)

 

10900 NE 4th Street, Suite 2300, Bellevue, WA   98004
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code (425) 635-7700

 

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on
which registered
Common stock, par value $0.0001 per share   OSRH   The Nasdaq Stock Market LLC
Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share   OSRHW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 8.01. Other Events.

As previously reported, the Company received a Staff Determination Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of Nasdaq’s determination to delist the Company’s common stock and warrants from the Nasdaq Capital Market for non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

 

On August 25, 2026, the Company submitted a request for a hearing before a Nasdaq Hearings Panel (the “Panel”), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, appealing the Staff’s delisting determination and requesting the continued listing of the Company’s securities on Nasdaq. As previously disclosed, because the Company was previously granted a second 180-day compliance period, the timely hearing request will not stay the scheduled suspension of trading in the Company’s securities, which remains scheduled for the opening of business on August 26, 2026. However, the timely hearing request is expected to stay the filing of a Form 25-NSE, and therefore the formal delisting of the Company’s securities from listing and registration on Nasdaq, pending the issuance of the Panel’s decision.

 

At the hearing, the Company intends to present a plan to evidence its ability to regain and sustain compliance with the applicable Nasdaq continued listing requirements. There can be no assurance that the Panel will grant the Company’s request for continued listing or that the Company will regain compliance with Nasdaq’s listing requirements.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the Company’s request for a hearing before the Panel, the anticipated suspension of trading in the Company’s securities, the potential filing of a Form 25-NSE, and the Company’s ability to regain or maintain compliance with Nasdaq’s listing requirements. These statements involve known and unknown risks and uncertainties, and actual results may differ materially. There can be no assurance that the Company will be granted a hearing, that any plan of compliance will be accepted by the Panel, or that the Company will maintain the listing of its securities on Nasdaq. The Company undertakes no obligation to update any forward-looking statements except as required by law.

 

1

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 25, 2026

 

  OSR HEALTH, INC.
       
  By:  /s/ Kuk Hyoun Hwang
    Name:  Kuk Hyoun Hwang
    Title: Chief Executive Officer

 

2

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Other Documents